Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 9,601–9,700 of 10,906
Cardiac effects of drugs and vaccines used to treat and prevent COVID-19
Cubeddu, L. X., & Tailor, M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95646-8.00048-2 · Cited by 1
Jin, T., Xu, G., Zhou, W., Shi, Y., & Wang, H. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70954
“Furthermore, the remarkable success of mRNA vaccines in combating the COVID-19 pandemic [229–232] has accelerated the development of circRNA-based vaccine platforms.”
Could mRNA delivery of OAS3 and RNase L provide a novel broad-spectrum antiviral therapy?
Yépez, K. R. E. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111822 · Cited by 1
Tyagi, P., Jain, K., & Basavaraddi, I. V. (2024) · Indian Journal of Physical Therapy and Research · doi:10.4103/ijptr.ijptr_129_23
Cheng, Y., Han, Y., Gu, X., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c12530
Morin‐Dewaele, M. (2023) · theses.fr (ABES) · doi:10.70675/3332ee05z67cez489cza3e8zb3843eed7d42
Cutaneous adverse effects of COVID-19 vaccines: what do we know so far?
Cernat, M. C., Ali, S., & Bumbăcea, R. S. (2021) · Alergologia · doi:10.26416/aler.5.2.2021.4898
Chang, H.-J., Goh, W.-P., Tsai, S.-C., et al. (2023) · Lecture notes in networks and systems · doi:10.1007/978-3-031-43824-0_7
Ess, G., Lew, A. S., Tippett, A., Salazar, L. W., Choi, C., Castro, K. D., Taylor, E. G., Reese, O., Momin, H., Ciric, C. R., et al. (2025) · Vaccines · doi:10.3390/vaccines14010045
Self-citationScheithauer, S., Bludau, A., Heinemann, S., Anton, M., & Knolle, P. A. (2022) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-022-03607-x
Ashby, E., Janes, H., Follmann, D. A., Gilbert, P. B., Zhou, H., Wang, X., Girard, B., Priddy, F. H., Kublin, J. G., Corey, L., et al. (2025) · American Journal of Epidemiology · doi:10.1093/aje/kwaf176 · Cited by 6
Self-citationHasanpourghadi, M., Novikov, M., Ambrose, R., Chekaoui, A., Newman, D., Ding, J.-B., Giles-Davis, W., Xiang, Z., Zhou, X., Liu, Q., et al. (2022) · bioRxiv · doi:10.1101/2022.03.17.484786
Salcedo, L. M. J., Feijóo, S., García, C., Alonso, A., Aguado, B., Ortiz, J., Figuera, A., & de la Cámara, R. (2023) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2023.014
mRNA Based SARS-CoV-2 Vaccines and Ongoing Researches
Hoşbul, T., Yılmaz, Ü. İ., Aydoğan, C. N., & Şahiner, F. (2021) · Journal of Molecular Virology and Immunology · doi:10.46683/jmvi.2020.20
Donohoe, K., Johannson, K. A., Manganas, H., Marcoux, V. S., & Ryerson, C. J. (2025) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2024-003008
van der Pol, S., Beck, E. C., Westra, T. A., et al. (2026) · medRxiv · doi:10.64898/2026.02.18.26346561
Theories of Contagion and Cancer
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0003
Von Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
Kim, H. J., Suh, J. H., Kim, M. H., Choi, M. G., & Chun, E. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051767 · Cited by 2
Lundstrom, K. H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-818731-9.00137-3
Persistent Rash After COVID-19 Vaccination: Answer
Gay, J. J., Trivedi, N., Simpson, S., et al. (2022) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000002299
Fant, P., Laurent, S., Désert, P., Combadière, B., Palazzi, X., Choudhary, S., Gervais, F., Broudic, K., Rossi, R., & Gauthier, B. E. (2025) · Toxicologic Pathology · doi:10.1177/01926233251326089
A Comparative Study on Different Approaches of COVID-19 Vaccines
Rahman, M. A., Chayon, R. M., Aziz, A., Faria, F. T. J., Islam, M. A., & Rahman, M. R. (2023) · European Journal of Pharmaceutical Research · doi:10.24018/ejpharma.2023.3.4.58
Dosis aplicadas contra COVID-19 por laboratorio en las entidades territoriales de Colombia
Pinzón, J. E. D. (2021) · Revista Repertorio de Medicina y Cirugía · doi:10.31260/repertmedcir.01217372.1278
Hussein, N. R., Abdulkareem, W. L., Rasheed, N. A., & Ameen, M. R. (2023) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.17.3.43 · Cited by 1
Chen, Z., Yang, J., Zheng, B., Yang, Y., Qiu, X., Zhou, H., Wang, R., & Xiong, H. (2026) · Angewandte Chemie · doi:10.1002/ange.202523579
Self-citationJanžič, U., Janžič, A., Agbarya, A., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12030535
Take Your Best Shot: Which SARS-CoV-2 Vaccine Should I Get?
Eckman, M. H., Powers‐Fletcher, M. V., Forrester, J. W., Fichtenbaum, C. J., Lofgren, R. P., & Smulian, A. G. (2021) · MDM Policy & Practice · doi:10.1177/23814683211031226
COVID-19 en receptores de trasplante renal: ¿qué hemos aprendido tras 18 meses de pandemia?
Fernández‐Ruiz, M. (2021) · Enfermería Nefrológica · doi:10.37551/s2254-28842021020
Jotwani, R., Pryor, K. O., & Goldstein, P. A. (2024) · doi:10.1093/med/9780197655979.003.0044
Beyond the blood: Tissue-resident immunity shapes SARS-CoV-2 vaccine antibody responsesPreprint
Schröter, J., van Dorp, C. H., Davis‐Porada, J., Teijaro, J. R., Färber, D. L., & Yates, A. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.23.740375
Ricke, D. O. (2022) · Research Square · doi:10.21203/rs.3.rs-1702797/v1
Safety Profile of SARS-CoV-2 Vaccination in Patients with Lupus Nephritis: A Retrospective Study
Petrou, D., Marinaki, S., Kriki, P. A., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020406
Th2 Suppression Through Antigen Liver Expression Using mRNA-LNP Technology
Arai, K., Toyonaga, H., Cheng, L., & Tanaka, H. (2025) · Biomedicines · doi:10.3390/biomedicines13092297 · Cited by 1
Jogi, M. K., Shikha, S., Singh, P., Sharma, D., Shreyansh, S., Mishra, P., Priyadarsini, A., Priyadarsini, A., Choudhary, D. K., Jain, M., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1846973
Advances and Challenges in Nanodelivery Systems for RNA Vaccines
Li, H., Zhao, Y., Yang, J., Guo, J., Cai, H., & Tong, A. (2026) · ACS Nano · doi:10.1021/acsnano.6c10327 · Cited by 2
Koide, A., Panchenko, T., Wang, C., Thannickal, S. A., Romero, L. A., Teng, K. W., Li, F.-Z., Akkapeddi, P., Corrado, A. D., Caro, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.03.454782 · Cited by 1
Bhattacharya, S., Bairagi, N., & Sarkar, B. (2026) · Computers & Industrial Engineering · doi:10.1016/j.cie.2026.112315
Stabilizing Anionic mRNA Lipid Nanoparticles by Cleavable Crosslinking of Cholesterol
Su, Y., Choy, J., Liu, X., Zhu, Y., Lin, J., Wei, C., Goodier, K. D., Yu, D. S., Cheng, L., Patel, M., et al. (2026) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6c06888
Kaplan, B., Pavel, S. T. I., Uygut, M. A., Tunc, M., Eröksüz, Y., Çelik, İ., EREN, E. E., Korukluoğlu, G., Kara, A., Özdarendeli, A., et al. (2025) · Vaccines · doi:10.3390/vaccines13020169 · Cited by 1
Montori, M., Martini, F., BLASIO, F. D., Buono, T., Quatraccioni, C., Guardati, P., CALZOLARI, M., ROSSI, C., Bendia, E., Menzo, S., et al. (2022) · Minerva Gastroenterology · doi:10.23736/s2724-5985.22.03134-5
Interpretations of Studies on SARS-CoV-2 Vaccination and Post-acute COVID-19 Sequelae
Gonçalves, B. P., Olliaro, P., Horby, P., Merson, L., & Cowling, B. J. (2024) · Epidemiology · doi:10.1097/ede.0000000000001720 · Cited by 1
Rapid growth and thematic shifts in mRNA therapeutics research catalyzed by the COVID-19 pandemic
Annadurai, P. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05173-4
“This literature is mostly based on just two definitive studies that show definitive large-scale clinical pharmacological validation of a platform for delivering both the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) vaccines on a Phase 3 trial (Baden et al. 2021; Polack et al. 2020).”
The impact of COVID-19 on patients with heart failure and valvular disease
Portera, M. V., DONALD, E. M., Ranard, L. S., & DeFilippis, E. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-14001-3.00013-3
Coupled carrier-message engineering for low-dose mRNA vaccination
Xu, J., Kim, J. G., Song, J., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103009
Systematic Modulation of the Lipid Composition Enables to Tune Liposome Cellular Uptake PathwaysPreprint
Mateos‐Maroto, A., Gai, M., Brückner, M., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4160452
Wu, X., Liang, C., Lei, Y., Peng, X., Zhang, Y., Yang, G., Yin, H., & Xu, K. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.22.550185
Ishii, H., Nomura, T., Yamamoto, H., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3924605
REGEN-COV as the First Line of Defense—A Single-Centre Experience
Popović, M., Đurović, V., Ljubičić, B., Kovačević, N., Sajinovic, S., Petrović, L., Ilić, T., & Golubović, S. (2026) · Life · doi:10.3390/life16010074
“Consistent with previous reports, patients in our cohort who were vaccinated against COVID-19 experienced lower rates of hospitalization compared with unvaccinated patients [23–25].”
RNA delivery to the corneal endothelium using charge-altering releasable transporters
Wang, S. K., Li, Z., Shah, S. H., Edwards, Q. A., Bouffard, R., Hines, E. S., Imventarza, J. A., Korte, S., Lawrence, M. S., Song, E., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady8161
Transforming mRNA drug design with AI: From UTR and codon optimization to coordinated design
Shi, Y., Zeng, C., Sheng, X., Zhang, X., Xing, Y., Zheng, M., & Li, X. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.06.013 · Cited by 2
Development, rollout, and challenges of COVID-19 vaccines in Japan and globally
Arashiro, T., & Suzuki, T. (2021) · Uirusu · doi:10.2222/jsv.71.41
Ghanem, H., Ghanem, S., & Almutawa, E. (2023) · Recent Patents on Biotechnology · doi:10.2174/1872208317666230612141930
Suh, J. H., Kim, H. J., Kim, M. H., Choi, M. G., & Chun, E. M. (2023) · medRxiv · doi:10.1101/2023.11.15.23298566
Intranasal circRNA vaccine elicits localized and safer antitumor immunity
Jiang, Z., Ke, Y., & Peng, Y. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.01.001
Bouton, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-80932-0.00031-8
Multisystem Inflammatory Syndrome in an Adult After COVID-19 Vaccination
Chien, K., Duffett, L. D., & Scarvelis, D. (2022) · Canadian Journal of General Internal Medicine · doi:10.22374/cjgim.v17i2.593
Anonymous (2021) · Journal de Pédiatrie et de Puériculture · doi:10.1016/j.jpp.2021.06.001
Mutoh, Y., Yamaguchi, T., Sakurai, K., Minato, Y., Izumisawa, T., Kaneko, T., Umemura, T., Mizutani, F., Soejima, K., Hagimoto, S., et al. (2026) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2026.103009
Introduction: The Tale of the Journey Through the Ocean of Longevity
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0001
Language and racial disparities in COVID-19 vaccination during pregnancy and lactation
Ukah, U. V., Haapala, J. L., Benítez, G. V., DeSilva, M. B., Vesco, K. K., Daida, Y. G., Sidebottom, A., Kharbanda, E. O., Ehresmann, K., Seburg, E. M., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128638
Programmable mRNA Nanotherapeutics through Logic Switch Design
Chen, P., Alhussan, A., Cullis, P. R., & Cabral, H. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00159
Khan, M. I., Sankaran, K. R., & Rahaman, S. O. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.23.707596
Multifunctional nanocomposites for precise control over drug delivery
Andretto, V. (2022) · theses.fr (ABES) · doi:10.70675/7a7f57fez25f2z41a0z9072z3f3cc2aef2d6
Application of synthetic biology in vaccine development
Dutta, A., Ash, D., Basu, B., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33649-2.00014-9
Healy, K., Pin, E., Chen, P., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3940632
The Study of the COVID-19 Virus: A Review
Forsythe, M. L. (2024) · The Open COVID Journal · doi:10.2174/0126669587296962240521114748
Immune Mechanisms and Translational Study Design in Viral Vaccine Development
Lim, S., & Martina, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135790
“Phase 1 studies assess safety and tolerability in a small group of healthy participants [5].”
Conservative Care and Outcomes for 2 Patients With Ramsay Hunt Syndrome
Joubert, S. V., & Alwazan, T. B. (2025) · Journal of Chiropractic Medicine · doi:10.1016/j.jcm.2025.09.011
Donat, N., Mellati, N., Frumento, T., Cirodde, A., Gette, S., Guitard, P. G., Hoffmann, C., Veber, B., & Leclerc, T. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285690
COVID-19 vaccine safety in adults: A narrative review of adverse reactions in ASEAN countries
Andini, P., Darmawan, E., Muflih, A., & Ridwan, M. (2026) · Scripta Medica · doi:10.5937/scriptamed57-60151
Lukaschek, K., Hofbauer, S., Dreischulte, T., Drey, M., Rottenkolber, M., Winter, S., Sebastião, M., Teupser, D., Gágyor, I., Hausen, A., et al. (2026) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000551288
“Additionally, non-hospitalized individuals in need of care were more frequently vaccinated against COVID-19, reinforcing evidence that vaccination reduces the risk of severe outcomes [51–53].”
Political Polarization and Healthcare Decision-Making: Evidence from a Vaccine ExperimentPreprint
Churchill, B., Gao, S. S., & Rong, R. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4990636
Hikichi, H., Fujioka, Y., Saga, A., Watanabe, K., Hasegawa, R., Moritoki, Y., & Ueki, S. (2024) · Cureus · doi:10.7759/cureus.63410 · Cited by 1
What’s New in Musculoskeletal Basic Science
Bahney, C. S., Stoddart, M. J., Miclau, T., & Marcucio, R. (2025) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.25.01234
Spiliopoulou, P., van Rensburg, H. J. J., Avery, L. M., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2214679/v1
Cusi, M. G., Giacomo, A. M. D., Anichini, G., Savellini, G. G., Terrosi, C., Gandolfo, C., & Maio, M. (2023) · Viruses · doi:10.3390/v15030614
Tomanguillo, J., Searls, L., Annie, F., Kemper, S. E., & Naravadi, V. V. R. (2023) · Cureus · doi:10.7759/cureus.34004
Humoral Immunogenicity of SARS-CoV-2 mRNA Primary Vaccination Among People with HIV
Nomah, D. K., Robles, A. G., Bruguera, A., Tiraboschi, J. M., Benet, S., García‐Pérez, J., Jiménez, P., Vilaró, I., Navarro, G., Sánchez‐Palomino, S., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14040893
“Vaccination has played a central role in reducing the burden of severe COVID-19 globally [5]. mRNA vaccines such as BNT162b2 and mRNA-1273 showed high efficacy in randomized clinical trials conducted in the general population [6,7].”
Madni, A. U. H., Hassan, N., Hameed, S. M., Satti, M. N., Ullah, R. H., Adnan, H., Mushtaq, M. F., & Faridi, T. A. (2025) · Pakistan BioMedical Journal · doi:10.54393/pbmj.v8i8.1299
Souza, D. V. D., Davidson, C. B., Pappis, L., Fontana, T., Oviedo, A. K. R. R., Martins, M. O., Fagan, S. B., & Machado, A. K. (2025) · Aracê. · doi:10.56238/arev7n1-060 · Cited by 1
SARS-COV-2 and Other mRNA Vaccines
Jackson, N. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_6
Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy
Repellin, M., Ugel, S., Sanctis, F. D., Coudert, L., Wang, T., Anselmi, C., Andretto, V., Scionti, I., Dimastromatteo, J., Sidi‐Boumedine, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115128 · Cited by 1
建部, 将., & 瀬尾, 龍. (2022) · Nippon Jibiinkoka Tokeibugeka Gakkai Kaiho(Tokyo) · doi:10.3950/jibiinkotokeibu.125.3_243
Characteristic Features of SARS CoV-2
Bakhat, S., & Taj, Y. (2021) · Journal of Bahria University Medical and Dental College · doi:10.51985/fnwg4302
Frauengesundheit – Frauenmedizin
(2023) · Elsevier eBooks · doi:10.1016/b978-3-437-23571-9.09981-8
Mask Use Scale: A Scale Development Study
Mamuk, R., & Di?siz, M. (2023) · Iranian Red Crescent Medical Journal · doi:10.32592/ircmj.2022.25.1.2284
COVID-19 Vaccination and Lethality Reduction: A Prospective Cohort Study in VenezuelaPreprint
Forero-Peña, D. A., Leyva, J. L., Valenzuela, M. V., Omaña-Ávila, Ó. D., Mendoza-Millán, D. L., Sánchez-Ytriago, E. A., Hachem, A. C. L.-E., Farro, K. R., Maita, A. K., González, R. D. C., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3813947/v1
Tendencias en la disciplina de la Visualización de Información
Pérez–Montoro, M. (2022) · Anuario ThinkEPI · doi:10.3145/thinkepi.2022.e16a02
Alkhorayef, N. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05697-9
COVID-19 Vaccines Side-Effects and Reaction Among Vaccinated Population in Saudi Arabia
Bakhuraysah, M. M., Bukhari, A. A., Gharib, A. F., & Alharbi, A. D. (2023) · Archives of Pharmacy Practice · doi:10.51847/khntseqjwk
The Application of Gene and Cell Therapies in Cardiac Repair
刘, 思. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.15123503
AI-driven advancements in vaccine development: From discovery to global deployment
Ali, A. M., Mushtaq, D., Qadri, S., Saman, S., Almuqdadi, H. T. A., Hindi, A. A., Neeraj, Jasim, O. M., Sharma, A., & Qazi, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44430-2.00001-3
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.